A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections
- Authors
- Matthews; Alpert, M.; Rahav, G.; Rill, D.; Zito, E.; Gardiner, D.; Pedersen, R.; Babinchak, T.; McGovern, P.C.; Armstrong, P.; Berbel, G.; Bernstein, J.; Bordon, J.; Bruno-Murtha, L.A.; Caprioli, R.; Casey, K.; Chiang, T.; Churukian, A.; Flynn, W.; Graham, D.; Hao, Z.; Kalassian, K.; Kohler, R.; Lee, J.; Lucasti, C.; Malanoski, G.; Ko, T.; Minnaganti, V.; Mogyoros, M.; Morgan, B.; Moss, C.; Muluk, S.; O'Riordan, W.; Polk, H.; Salvaggio, M.; Smith, L.; Smith, R.; Scott Stienecker, R.; Suh, B.; Vazquez, J.; Wessolossky, M.; Zenilman, J.; Sanchez, P.; Baird, I.; Callahan, C.; Schrock, C.G.; Bochan, M.R.; Somero, M.; Klein, S.R.; Bellows, C.; D'Hooghe, A.; Ceulemans, F.; Gaillat, J.; Garo, B.; Eckmann, C.; Haier, J.; Suter, F.; Bertani, A.; Acin, F.; Jiménez-Mejías, M.E.; Blanes, I.; Regueiro, D.S.; Cakir, N.; Saba, R.; Giladi, M.; Kanj-Sharara, S.; Ahmed al Thaqafi, A.O.; Ng, W.-M.; Burd, A.; Kurlekar, U.; Rao, N.R.; Devarajan, T.; Choi, J.; Kim, Y.; Pai, H.; Park, Y.-S.; Kumar, S.; Chow, T.S.; Crisostomo, A.; Erasmo, A.; Low, J.; Basson; Breedt, J.; Matthews; Ross, D.P.; Lin, H.-H.; Liao, C.-H.; Kung, H.-C.; Chinswangwatanakul, V.; Malathum, K.; Tantawichien, T.; Sergio Ricardo Filho Penteado; Cardoso, F.; Gomez, R.F.; Velazquez, D.F.; Poirier, A.; Valiquette, L.; Weiss, K.; Grimard, D.; Embil, J.M.A.; Sanche, S.E.; Smith, K.; Chouinard, S.; Dolcé, P.
- Issue Date
- Nov-2012
- Publisher
- BIOMED CENTRAL LTD
- Keywords
- CSSSI; Glycylcycline; Skin and skin structure infection; Tigecycline
- Citation
- BMC Infectious Diseases, v.12
- Journal Title
- BMC Infectious Diseases
- Volume
- 12
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17484
- DOI
- 10.1186/1471-2334-12-297
- ISSN
- 1471-2334
- Abstract
- Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality.Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with cSSSI received tigecycline (100 mg initial dose, then 50 mg intravenously every 12 hrs) or ampicillin-sulbactam 1.5-3 g IV every 6 hrs or amoxicillin-clavulanate 1.2 g IV every 6-8 hrs. Vancomycin could be added at the discretion of the investigator to the comparator arm if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed or suspected within 72 hrs of enrollment. The primary endpoint was clinical response in the clinically evaluable (CE) population at the test-of-cure (TOC) visit. Microbiologic response and safety were also assessed. The modified intent-to-treat (mITT) population comprised 531 subjects (tigecycline, n = 268; comparator, n = 263) and 405 were clinically evaluable (tigecycline, n = 209; comparator, n = 196).Results: In the CE population, 162/209 (77.5%) tigecycline-treated subjects and 152/196 (77.6%) comparator-treated subjects were clinically cured (difference 0.0; 95% confidence interval [CI]: -8.7, 8.6). The eradication rates at the subject level for the microbiologically evaluable (ME) population were 79.2% in the tigecycline treatment group and 76.8% in the comparator treatment group (difference 2.4; 95% CI: -9.6, 14.4) at the TOC assessment. Nausea, vomiting, and diarrhea rates were higher in the tigecycline group.Conclusions: Tigecycline was generally safe and effective in the treatment of cSSSIs.Trial registration: ClinicalTrials.gov NCT00368537. © 2012 Matthews et al.; licensee BioMed Central Ltd.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17484)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.